Workday's (NASDAQ:WDAY) Q1: Beats On Revenue
Finance and HR software company Workday (NASDAQ:WDAY) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 12.6% year on year to $2.24 billion. Its non-GAAP profit of $2.23 per share was 11% above analysts' consensus estimates.
Is now the time to buy Workday? Find out in our full research report.
Revenue: $2.24 billion vs analyst estimates of $2.22 billion (12.6% year-on-year growth, 1% beat)
Adjusted EPS: $2.23 vs analyst estimates of $2.01 (11% beat)
Adjusted Operating Income: $677 million vs analyst estimates of $621.7 million (30.2% margin, 8.9% beat)
Q2 guidance for subscription revenue beats expectations, but full-year subscription revenue guidance in line
Operating Margin: 1.7%, down from 3.2% in the same quarter last year
Free Cash Flow Margin: 18.8%, down from 46.4% in the previous quarter
Billings: $1.57 billion at quarter end, up 6.4% year on year
Market Capitalization: $71.83 billion
"Workday delivered another solid quarter, a testament to the durability of our business and the relevance of our platform as CEOs increasingly turn to us to drive efficiency, agility, and growth," said Carl Eschenbach, CEO, Workday.
Founded by industry veterans Aneel Bushri and Dave Duffield after their former company PeopleSoft was acquired by Oracle in a hostile takeover, Workday (NASDAQ:WDAY) provides cloud-based software for organizations to manage and plan finance and human resources.
A company's long-term sales performance is one signal of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last three years, Workday grew its sales at a 17.2% compounded annual growth rate. Although this growth is acceptable on an absolute basis, it fell slightly short of our standards for the software sector, which enjoys a number of secular tailwinds.
This quarter, Workday reported year-on-year revenue growth of 12.6%, and its $2.24 billion of revenue exceeded Wall Street's estimates by 1%.
Looking ahead, sell-side analysts expect revenue to grow 12.8% over the next 12 months, a deceleration versus the last three years. Despite the slowdown, this projection is above the sector average and suggests the market sees some success for its newer products and services.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Billings is a non-GAAP metric that is often called 'cash revenue' because it shows how much money the company has collected from customers in a certain period. This is different from revenue, which must be recognized in pieces over the length of a contract.
Workday's billings punched in at $1.57 billion in Q1, and over the last four quarters, its growth slightly outpaced the sector as it averaged 12.9% year-on-year increases. This alternate topline metric grew slower than total sales, meaning the company recognizes revenue faster than it collects cash - a headwind for its liquidity that could also signal a slowdown in future revenue growth.
The customer acquisition cost (CAC) payback period represents the months required to recover the cost of acquiring a new customer. Essentially, it's the break-even point for sales and marketing investments. A shorter CAC payback period is ideal, as it implies better returns on investment and business scalability.
Workday does a decent job acquiring new customers, and its CAC payback period checked in at 47.5 months this quarter. The company's relatively fast recovery of its customer acquisition costs gives it the option to accelerate growth by increasing its sales and marketing investments.
It was good to see Workday narrowly top analysts' revenue expectations this quarter. Looking ahead, Q2 subscription revenue guidance was ahead of Wall Street Consensus, but full-year subscription revenue guidance was roughly in line. Additionally, its billings missed. Overall, this was a mixed quarter. The stock traded down 3.2% to $263.44 immediately after reporting.
Workday's earnings report left more to be desired. Let's look forward to see if this quarter has created an opportunity to buy the stock. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Bad ‘vibes' may be having a bigger impact on the economy now
There has been a disconnect in recent years between the so-called soft economic data and the hard data as weak readings on consumer confidence didn't always translate to lower payrolls or GDP. But that may be changing as key buffers that propped up spending are disappearing, according to NerdWallet senior economist Elizabeth Renter. Americans used to say one thing about their feelings on the economy and do something else with their actual dollars. But that may be changing. The disconnect between weak readings on consumer confidence versus solid employment, income and GDP data was previously described as a 'vibecession' by economist Kyla Scanlon, who first used the term in her 2022 Substack post. The last vibecession hit as inflation was at the highest levels in more than 40 years, while an aggressive rate-hiking campaign from the Federal Reserve spiked borrowing costs, making auto loans and mortgages more expensive. But consumers continued to spend as the labor market remained robust. And aside from a brief dip in GDP, the economy avoided a recession. Confidence surveys also increasingly reflected partisan differences more than the actual economy. Fast forward to 2025. Consumer sentiment collapsed after President Donald Trump launched his trade war, and GDP shrank again, skewed by a rush to buy imported goods ahead of higher tariffs. Still, payrolls have held up, and inflation hasn't been as affected by tariffs as feared. But while sentiment recovered a bit after Trump postponed his highest tariff rates, it's still 20% below December 2024 levels. 'Despite this month's notable improvement, consumers remain guarded and concerned about the trajectory of the economy,' the most recent University of Michigan survey said. At the same time, the Trump administration is slashing spending and jobs, with ripple effects reaching contractors and even certain real estate markets. Businesses that are uncertain about the economy and the direction of tariffs have slowed hiring. Student-loan delinquencies are up, and AI is eliminating many entry-level jobs that once went to newly minted college graduates. Then there's oil prices, which have jumped since Israel launched airstrikes on Iran. The cumulative effect is taking a toll. 'I don't think the U.S. consumer has grown numb or blind to the headlines and economic risk—over the past month we've seen some sentiment scores rise slightly, but we have to think about where they were rising from,' Elizabeth Renter, senior economist at NerdWallet, said in a note on Friday. 'A little bit better doesn't necessarily mean good, even if it might mean hopeful.' As a result, it's getting harder to dismiss the so-called soft data on the economy and focus instead on the hard data. That's as Fed Chairman Jerome Powell has said he and his fellow policymakers won't act on rates until the hard data on unemployment and inflation gives them a clear reason to. But the soft stuff may be leaking into the hard stuff. 'Unlike a few years ago, the 'vibes' now stand to have a greater impact on behavior, and thus the health of the economy,' Renter wrote. 'That's because unlike a few years ago, people don't have the luxury of easily stumbling into a better job or relying on excess savings and debt payment forbearances.' In fact, household debt is rebounding to pre-pandemic levels and beyond, eroding the ability to absorb an unexpected expense or job loss, she added. Bill Adams, chief economist at Comerica Bank, similarly drew a direct line between consumer sentiment and actual spending. Digging into the May retail sales report, he noted that consumers didn't just pull back on durable goods like electronics and cars, which fell after an earlier jump to get ahead of tariffs, they also reined in spending on daily expenses like groceries and restaurants. Spending at building material and garden supply stores also saw big drops, suggesting less residential investment in home improvements. 'With declines visible in unrelated categories, it looks like weak consumer confidence was to blame for the pullback in consumer spending last month,' Adams wrote. This story was originally featured on
Yahoo
an hour ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool
Bloomberg
an hour ago
- Bloomberg
Trump's Twists and Turns Over Iran Leave Oil Traders Hanging
The oil market is wrestling with Donald Trump's next act in the conflict between Iran and Israel, with the US president's every utterance over the fighting seemingly capable of spiking or crashing prices. In a wild week, Brent futures have surged 11% from before Israel attacked its nemesis, but with sharp moves up and down from one day to the next.
